Forward to: Corp Dev

Biotech M&A Intelligence
Workflows

Ten agent workflows for Corporate Development — biotech acquisition signal detection, licensing deal tracking, partnership intelligence, strategic transaction monitoring, target valuation, due diligence signals, integration tracking, divestiture opportunities, deal structure analysis, and M&A strategy dashboard — enabling data-driven transaction decisions powered by comprehensive domain intelligence.

1Acquisition Signal Detection

AI agent detects biotech M&A signals by monitoring company domains for strategic review announcements, advisor hiring, leadership departures, and cash burn acceleration that precede acquisition activity.

1
Detect M&A Precursor Signals
/investors/leadership/press/careersOpenPageRank
BIOTECH M&A SIGNAL DETECTION ════════════════════════════════════════════════════════ HIGH-PROBABILITY ACQUISITION TARGETS: immunomedics-successors.com — Rare Disease Biotech /investors: "Exploring strategic alternatives" language added /leadership: CFO departed + Centerview Partners engaged /careers: Hiring freeze — all postings removed SIGNAL: 94% probability of sale — $4-7B estimated value ACTION: Pipeline overlap in rare hematology — prepare bid karuna-tx-example.com — CNS Biotech /investors: Board exploring "value-maximizing alternatives" /press: Positive Phase 3 data in schizophrenia SIGNAL: 82% probability — multiple bidders likely M&A PIPELINE SUMMARY: Targets monitored: 120 biotech companies High-probability signals: 5 this quarter Estimated addressable value: $25-45B

2Licensing Deal Intelligence

AI agent monitors biotech partnership and licensing activity to identify in-licensing opportunities, out-licensing trends, and optimal deal structures across therapeutic areas.

1
Track Licensing Activity
/press/investors/partnersIAB Categories
LICENSING DEAL TRACKER — Q1 2026 ════════════════════════════════════════════════════════ merck.com + modernatx.com /press: $1.8B expansion — cancer vaccine collaboration Deal: $250M upfront + $1.55B milestones + royalties SIGNAL: mRNA-oncology space heating up — evaluate own assets roche.com + recursion.com /press: $150M upfront — AI-discovered neuroscience targets /partners: 40-target exclusive collaboration SIGNAL: AI drug discovery partnerships increasing in value LICENSING MARKET TRENDS: Total deal value (Q1 2026): $18.4B (+22% YoY) Average upfront payment: $180M (Phase 2 assets) Hottest areas: Obesity, ADCs, Cell therapy

3Partnership Opportunity Assessment

AI agent identifies partnership opportunities by analyzing biotech company domains for co-development signals, platform complementarity, and strategic alignment.

1
Identify Partnership Opportunities
/products/partners/investorsOpenPageRank
PARTNERSHIP OPPORTUNITY ASSESSMENT ════════════════════════════════════════════════════════ HIGH-FIT PARTNERSHIP CANDIDATES: arcturus-therapeutics.com /products: LUNAR LNP delivery — complementary to our mRNA assets /partners: Currently 2 big pharma partners /investors: Market cap $1.8B — open to additional deals FIT SCORE: 92/100 — LNP delivery for our pipeline dynavax.com /products: CpG 1018 adjuvant — world-class adjuvant platform /partners: 4 active collaborations FIT SCORE: 87/100 — Adjuvant for our vaccine programs PARTNERSHIP WINDOW CLOSING: seagenbio-example.com — ADC platform SIGNAL: 3 competing offers — act within 30 days

4Target Company Valuation

AI agent synthesizes domain signals to estimate acquisition target valuations using multiple data points — pipeline assets, commercial readiness, team quality, and competitive positioning.

1
Generate Target Valuations
/investors/products/leadership/careersOpenPageRank
TARGET VALUATION INTELLIGENCE ════════════════════════════════════════════════════════ example-biotech-target.com — Rare Disease /investors: Market cap $3.2B | Cash $890M /products: 2 Phase 3 + 1 approved product /leadership: Team from Alexion, BioMarin /careers: +45% commercial hiring — launch prep VALUATION ESTIMATE: rNPV pipeline value: $5.8-7.2B Synergy value: $800M-1.2B Implied premium to current: 80-125% Recommended bid range: $5.8-6.4B

5Digital Due Diligence

AI agent performs domain-based due diligence on acquisition targets — analyzing web presence, digital maturity, technology infrastructure signals, and online reputation.

1
Run Digital Due Diligence
/about/careers/securityDomain AgesOpenPageRank
DIGITAL DUE DILIGENCE REPORT ════════════════════════════════════════════════════════ target-biotech.com Domain Age: 4,200 days | PageRank: 6.2 /about: 340 employees | 3 office locations /security: SOC 2 Type II certified /careers: Active postings across 8 departments DIGITAL HEALTH ASSESSMENT: Web presence maturity: HIGH (8/10) Technology stack: Modern (AWS + React) Compliance posture: Strong — SOC 2 + HIPAA Brand reputation: Positive sentiment 87% RED FLAGS: /legal: 1 pending patent litigation disclosed /investors: Key customer concentration risk (top 3 = 62%)

6Integration Success Tracking

AI agent monitors post-acquisition integration signals by tracking domain changes, career page updates, leadership announcements, and brand consolidation — providing early indicators of integration success or risk.

1
Monitor Integration Signals
/careers/leadership/pressOpenPageRank
POST-ACQUISITION INTEGRATION TRACKER ════════════════════════════════════════════════════════ acquired-biotech.com — Acquired 6 months ago /careers: -42% total postings vs pre-acquisition /leadership: 3 of 8 C-suite departed post-close /press: No new press releases in 45 days SIGNAL: Integration challenges — talent attrition risk successful-acquisition.com — Acquired 12 months ago /careers: +28% postings — growth maintained /leadership: Full leadership team retained /press: Joint R&D milestones announced monthly SIGNAL: Successful integration — value creation on track

7Divestiture Opportunity Detection

AI agent identifies divestiture opportunities by monitoring large pharma domains for non-core asset signals — portfolio rationalization announcements, strategic review language, and declining investment in specific therapeutic areas.

1
Detect Divestiture Signals
/investors/press/productsIAB Categories
DIVESTITURE OPPORTUNITY INTELLIGENCE ════════════════════════════════════════════════════════ sanofi.com — Consumer Health /investors: "Strategic review of consumer division" announced /press: Opella consumer health spin-off proceeding OPPORTUNITY: $15-20B unit — potential carved-out acquisition novartis.com — Generics/Biosimilar /investors: Sandoz successfully spun off /press: Further portfolio simplification expected SIGNAL: Additional non-core assets may become available DIVESTITURE PIPELINE: Large pharma strategic reviews active: 4 Estimated divestable assets: $35-50B total value

8Deal Structure Analysis

AI agent analyzes recent biotech deal structures to inform negotiation strategy — tracking upfront payments, milestone structures, royalty rates, and contingent value rights across comparable transactions.

1
Analyze Deal Structures
/investors/press/legalIAB Categories
BIOTECH DEAL STRUCTURE BENCHMARKS ════════════════════════════════════════════════════════ RECENT COMPARABLE ACQUISITIONS: AbbVie + ImmunoGen: $10.1B | 97% premium | All cash Pfizer + Seagen: $43B | 33% premium | Cash + debt AstraZeneca + Gracell: $1.2B | 85% premium | Cash LICENSING DEAL BENCHMARKS: Phase 2 oncology: Upfront $100-300M + milestones 3-5x Phase 1 rare disease: Upfront $50-150M + milestones 4-8x Platform deals: Upfront $150-500M + per-target milestones KEY TRENDS: CVR usage: Increasing — 30% of deals include CVRs Premium to 30-day VWAP: Average 55-75% Breakup fees: 3-5% standard

9Competitive Bidding Intelligence

AI agent monitors signals that indicate competitive bidding situations — tracking multiple advisors, board meeting frequency, unusual stock movements, and media speculation to assess competitive dynamics.

1
Assess Competitive Bid Dynamics
/investors/press/leadershipOpenPageRank
COMPETITIVE BIDDING ASSESSMENT ════════════════════════════════════════════════════════ target-oncology-biotech.com /investors: Dual financial advisor engagement detected /leadership: Board expanded — 2 new independent directors /press: Multiple "sources familiar" media reports LIKELY BIDDERS DETECTED: merck.com — Strong pipeline fit, cash available roche.com — Complementary oncology portfolio abbvie.com — Immunology synergies SIGNAL: 3+ bidders identified — expect premium escalation RECOMMENDATION: Set walk-away price at $8.5B (120% premium)

10M&A Strategy Dashboard

AI agent synthesizes all M&A intelligence into an executive dashboard — providing leadership with real-time visibility into deal pipeline, target valuations, and transaction dynamics.

1
Generate M&A Intelligence Dashboard
/investors/press/leadershipOpenPageRankIAB Categories
M&A DASHBOARD — FEBRUARY 2026 ════════════════════════════════════════════════════════ DEAL PIPELINE: Targets monitored: 120 companies High-probability signals: 5 active In-licensing opportunities: 14 evaluating MARKET CONDITIONS: Biotech M&A volume (YTD): $68B (+35% YoY) Average premium: 65% to 30-day VWAP OUR POSITION: Firepower: $12B available (cash + debt capacity) Active bids: 2 in diligence
2
Generate M&A Report

Biotech M&A Report — February 2026

EXECUTIVE SUMMARY ──────────────────────────────────────── Acquisition targets monitored: 120 domains Licensing opportunities tracked: 45 active Post-acquisition integrations: 3 being monitored Deal flow this quarter: $18.4B in announced value KEY INSIGHTS M&A market accelerating — large pharma deploying cash aggressively. Oncology and obesity assets commanding premium valuations. AI drug discovery platforms increasingly valued as strategic assets. CVR structures becoming standard for binary clinical outcomes. Integration success rate improved when leadership retained.
Get in Touch

Interested in AI Agent Domain Intelligence?

For pricing, subscription options, custom database builds, or enterprise partnerships — contact us below.

Power Your AI Agents with Domain Intelligence

Subscribe to the AI Agent Domain Database — continuous access to 100M+ domains, 20 page types each, quarterly refreshes, and real-time change signals.

AI Agent Database View Pricing

Annual subscription includes quarterly data refreshes, change detection alerts, and priority API access.